RTP Mobile Logo
Data + Perspectives: Clinical Investigators Discuss the Current and Future Management of Ovarian Cancer (Webinar Video Proceedings)
Released April 2022

Featuring perspectives from Drs Mansoor Mirza, Kathleen Moore and David O’Malley, moderated by Dr Robert Coleman. Published April 5, 2022. (Webinar Video Proceedings)

CE Disclosures and Faculty Information

    This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of ovarian cancer.


    • Consider available clinical research findings with the use of PARP inhibitors as maintenance therapy after first-line platinum-based chemotherapy for advanced ovarian cancer, and counsel appropriate patients regarding personalized treatment recommendations.
    • Assess available clinical trial data with and approved indications for FDA-endorsed PARP inhibitors for recurrent, platinum-sensitive and multiregimen-refractory ovarian cancer to optimally incorporate these agents into patient care.
    • Appreciate the biologic rationale for and published clinical research data with the use of PARP inhibitors in combination with other systemic therapies, and consider clinical and research implications of these findings for ovarian cancer management.
    • Recognize the rationale for targeting folate receptor alpha and sodium-dependent phosphate transport protein 2b (NaPi2b) in ovarian cancer, and consider research findings with and the role of novel approaches to therapeutically exploit these potential biomarkers.
    • Describe the scientific rationale for the use of tumor treating fields (TTFs) as a therapeutic approach for ovarian cancer, and appraise the available efficacy and safety data with TTFs in combination with chemotherapy for recurrent advanced disease.
    • Recall the design of ongoing clinical trials evaluating novel agents and strategies for ovarian cancer, and counsel appropriate patients about availability and participation.
    • Incidence and detection of germline and somatic BRCA mutations and homologous recombination deficiency (HRD) in patients with advanced ovarian cancer; role of BRCA and HRD status in treatment decision-making for newly diagnosed advanced ovarian cancer.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    Research To Practice designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of these CME activities, which includes participation in the evaluation components and short post-tests, enables the participant to earn up to 1.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/SGO22Ovarian/CME.

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

    Mansoor Raza Mirza, MD
    Chief Oncologist
    Copenhagen University Hospital
    Medical Director
    Nordic Society of Gynaecological Oncology – Clinical Trial Unit
    Chairman, European Network of Gynaecological Trial Groups
    Vice President, European Society of Gynaecological Oncology
    Copenhagen, Denmark

    Advisory Board (Invited Speaker, Personal): AstraZeneca Pharmaceuticals LP, GlaxoSmithKline; Advisory Board (Personal): Allarity Therapeutics, AstraZeneca Pharmaceuticals LP, BIOCAD, Boehringer Ingelheim Pharmaceuticals Inc, GlaxoSmithKline, Karyopharm Therapeutics, Merck, Roche Laboratories Inc, Zai Lab; Ownership Interest (Member of Board of Directors): Karyopharm Therapeutics, Sera Prognostics.

    Kathleen N Moore, MD, MS
    Virginia Kerley Cade Chair in Developmental Therapeutics
    Associate Director for Clinical Research
    Director, Early Phase Drug Development
    Stephenson Cancer Center at the University of Oklahoma HSC
    Professor, Section of Gynecologic Oncology
    Associate Program Director, Gynecologic Oncology Fellowship
    University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma

    Advisory Committee: Alkermes, Aravive Inc, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Eisai Inc, Elevar Therapeutics, EMD Serono Inc, Genentech, a member of the Roche Group, Hengrui Therapeutics Inc, I-Mab Biopharma, ImmunoGen Inc, IMXmed, Lilly, Merck, Mereo BioPharma, Mersana Therapeutics Inc, Novartis, Onconova Therapeutics Inc, OncXerna Therapeutics Inc, Tarveda Therapeutics, Tesaro, A GSK Company, VBL Therapeutics; Consulting Agreement: AstraZeneca Pharmaceuticals LP; Contracted Research: Lilly, Merck, PTC Therapeutics; Data and Safety Monitoring Board/Committee: SQZ Biotech.

    David M O'Malley, MD
    Division Director, Gynecologic Oncology
    The Ohio State University and The James Cancer Center
    Columbus, Ohio

    Funding for Clinical Research: AbbVie Inc, Agenus Inc, Ajinomoto Co Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Clovis Oncology, Daré Bioscience, Eisai Inc, EMD Serono Inc, Ergomed Plc, Genentech, a member of the Roche Group, Genmab, GOG Foundation Inc, ImmunoGen Inc, Iovance Biotherapeutics, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Ludwig Institute for Cancer Research Ltd, Merck, Merck Serono, Mersana Therapeutics Inc, New Mexico Cancer Care Alliance, Novocure Inc, PRA Health Sciences, Regeneron Pharmaceuticals Inc, Seagen Inc, Stemcentrx, Sumitomo Dainippon Pharma Oncology Inc, Syneos Health, Tesaro, A GSK Company, TRACON Pharmaceuticals Inc, VentiRx Pharmaceuticals Inc, Yale University; Personal Fees (Consulting and/or Advisory Boards): AbbVie Inc, Ambry Genetics, Amgen Inc, Arquer Diagnostics, AstraZeneca Pharmaceuticals LP, Celsion Corporation, Clovis Oncology, Corcept Therapeutics, Eisai Inc, Elevar Therapeutics, Genentech, a member of the Roche Group, GOG Foundation Inc, ImmunoGen Inc, InxMed, Iovance Biotherapeutics, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Merck, Mersana Therapeutics Inc, Novartis, Novocure Inc, Regeneron Pharmaceuticals Inc, Roche Diagnostics MSA, Seagen Inc, Sorrento Therapeutics, Sumitomo Dainippon Pharma Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, Toray; Personal Fees: Agenus Inc, Myriad Genetic Laboratories Inc, Rubis, Tarveda Therapeutics.

    Robert L Coleman, MD
    Chief Scientific Officer
    US Oncology Research
    Gynecologic Oncology
    The Woodlands, Texas

    Advisory Committee: Agenus Inc, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Janssen Biotech Inc, Merck, Novartis, OncXernaTherapeutics Inc, Onxeo; Consulting Agreements: AbbVie Inc, Agenus Inc, Alkermes, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Genentech, a member of the Roche Group, Genmab, GlaxoSmithKline, Gradalis Inc, ImmunoGen Inc, Incyte Corporation, Janssen Biotech Inc, Merck, Myriad Genetic Laboratories Inc, Novartis, OncXerna Therapeutics Inc, Onxeo, Seagen Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Genentech, a member of the Roche Group, ImmunoGen Inc, Merck, Novartis; Data and Safety Monitoring Board/Committee: GOG Foundation Inc, VBL Therapeutics; Employment: Texas Oncology.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, ImmunoGen Inc, Merck, Mersana Therapeutics Inc and Novocure Inc.

    Release date: April 2022
    Expiration date: April 2023

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):